We are live on ! Find out more
PJP icon

Invesco Pharmaceuticals ETF

90 hedge funds and large institutions have $113M invested in Invesco Pharmaceuticals ETF in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 22 increasing their positions, 31 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

6% more capital invested

Capital invested by funds: $107M → $113M (+$6.24M)

1.41% more ownership

Funds ownership: 14.23%15.64% (+1.4%)

9% less funds holding

Funds holding: 9990 (-9)

29% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 31

54% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 13

Holders
90
Holders Change
-9
Holders Change %
-9.09%
% of All Funds
2.24%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
6
Increased
22
Reduced
31
Closed
13
Calls
$1.65M
Puts
Net Calls
+$1.65M
Net Calls Change
+$394K
Name Holding Trade Value Shares
Change
Change in
Stake
DADC
101
D.A. Davidson & Co
Montana
-$6K -99 Closed
OIA
102
OneDigital Investment Advisors
Kansas
-$5K -81 Closed

PJP Hedge Fund Activity: Q3 2017 in Review

90 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q3 2017, worth a combined $113M — up 5.8% from $107M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of PJP and 6 opened new positions — a net loss of 7 holders — while 31 trimmed existing stakes and 22 added.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $14.3M. The largest seller was Atria Investments, exiting entirely with an estimated $3M sold.

  • 90 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q3 2017, down from 99 in Q2 2017.
  • Funds reported $113M of Invesco Pharmaceuticals ETF stock for Q3 2017, up 5.8% quarter-over-quarter.
  • 6 funds opened new Invesco Pharmaceuticals ETF positions in Q3 2017 and 13 closed out, a net change of -7 holders.
  • The largest Invesco Pharmaceuticals ETF buyer in Q3 2017 was Two Sigma Securities, an estimated $14.3M added.
  • The largest Invesco Pharmaceuticals ETF seller in Q3 2017 was Atria Investments, an estimated $3M sold.

Based on aggregated 13F filings for Q3 2017.